The resulting iron buildup after decades can cause damage to many tissues, including the heart. This can increase the rate of ...

Biologic therapies targeting eosinophilic inflammation hold promise for COPD management. Realising their benefits will ...

A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with comorbid COPD.

THE NHS has issued a plea for people with chronic obstructive pulmonary disease (COPD) to follow three simple steps to protect their lungs ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m ...

Regardless of blood eosinophil count threshold, adults with COPD and an eosinophilic phenotype experienced significantly fewer moderate/severe exacerbations in a year with mepolizumab vs. placebo, ...

One of the most common genetic diseases, AATD, involves the retention of misfolded alpha 1 antitrypsin (AAT) in hepatocytes, ...

Hanlim University Medical Center (Director Kim Yong-sun) obtained the highest grade in the adequacy evaluation of chronic ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

Operator: Good morning, and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update ...

The American Lung Association Research Institute is investing $22 million to advance research and care for lung disease, ...